Loading...
XASX
FPH
Market cap11bUSD
Apr 03, Last price  
31.48AUD
1D
0.00%
1Q
-7.90%
Jan 2017
284.37%
Name

Fisher & Paykel Healthcare Corporation Ltd

Chart & Performance

D1W1MN
No data to show
P/E
152.52
P/S
11.50
EPS
0.23
Div Yield, %
0.68%
Shrs. gr., 5y
0.28%
Rev. gr., 5y
11.30%
Revenues
1.76b
+18.24%
241,136,000289,547,000349,242,000345,966,000485,516,000474,755,000467,680,000466,726,000507,250,000568,602,000644,013,000738,745,431796,785,293907,090,1961,029,311,9291,233,448,8931,791,400,9131,521,301,5841,486,891,5781,758,100,000
Net income
133m
-47.02%
61,405,00069,965,00057,605,00035,276,00062,233,00071,631,00052,466,00064,110,00077,053,00097,053,000113,173,000143,425,000169,152,000190,200,000209,200,000287,300,000524,200,000376,900,000250,300,000132,600,000
CFO
430m
+92.69%
66,380,45282,443,58956,346,00038,375,87651,318,835106,508,33052,244,85273,981,87569,349,32697,644,686144,023,540130,487,997177,379,035233,050,234243,190,664311,316,533574,973,304300,388,519222,949,498429,600,000
Dividend
Jun 26, 20240.21374 AUD/sh
Earnings
May 27, 2025

Profile

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It also provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers Airvo 2, a humidified nasal high flow system; Optiflow, a nasal high flow therapy; and F&P 850 System, a noninvasive and invasive ventilation system. In addition, it provides infant respiratory products, such as resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products, including humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, humidifiers, and accessories. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
URL
https://www.fphcare.com/
IPO date
Nov 13, 2001
Employees
6,391
Domiciled in
NZ
Incorporated in
NZ

Valuation

Title
NZD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
1,758,100
18.24%
1,486,892
-2.26%
Cost of revenue
1,389,400
1,168,941
Unusual Expense (Income)
NOPBT
368,700
317,951
NOPBT Margin
20.97%
21.38%
Operating Taxes
103,100
72,725
Tax Rate
27.96%
22.87%
NOPAT
265,600
245,226
Net income
132,600
-47.02%
250,300
-33.59%
Dividends
(145,500)
(195,700)
Dividend yield
1.05%
1.35%
Proceeds from repurchase of equity
3,000
3,000
BB yield
-0.02%
-0.02%
Debt
Debt current
96,200
21,300
Long-term debt
167,800
166,993
Deferred revenue
42,493
Other long-term liabilities
39,100
26,473
Net debt
182,000
(18,464)
Cash flow
Cash from operating activities
429,600
222,949
CAPEX
(316,800)
(197,772)
Cash from investing activities
(339,000)
(10,577)
Cash from financing activities
(128,700)
(184,481)
FCF
8,468
(14,901)
Balance
Cash
82,000
113,253
Long term investments
93,504
Excess cash
132,413
Stockholders' equity
1,764,200
1,644,229
Invested Capital
1,987,300
1,653,368
ROIC
14.59%
16.17%
ROCE
18.50%
17.78%
EV
Common stock shares outstanding
586,179
581,631
Price
23.66
-4.83%
24.86
10.73%
Market cap
13,868,994
-4.08%
14,459,345
11.05%
EV
14,050,994
14,440,881
EBITDA
483,000
410,613
EV/EBITDA
29.09
35.17
Interest
18,200
6,271
Interest/NOPBT
4.94%
1.97%